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Abstract: Overactivity of the sympathetic nervous system and central endothelins (ETs) are
involved in the development of hypertension. Besides the well-known brain structures involved
in the regulation of blood pressure like the hypothalamus or locus coeruleus, evidence suggests
that the olfactory bulb (OB) also modulates cardiovascular function. In the present study, we
evaluated the interaction between the endothelinergic and catecholaminergic systems in the OB of
deoxycorticosterone acetate (DOCA)-salt hypertensive rats. Following brain ET receptor type A (ETA)
blockade by BQ610 (selective antagonist), transcriptional, traductional, and post-traductional changes
in tyrosine hydroxylase (TH) were assessed in the OB of normotensive and DOCA-salt hypertensive
rats. Time course variations in systolic blood pressure and heart rate were also registered. Results
showed that ETA blockade dose dependently reduced blood pressure in hypertensive rats, but it
did not change heart rate. It also prevented the increase in TH activity and expression (mRNA
and protein) in the right OB of hypertensive animals. However, ETA blockade did not affect
hemodynamics or TH in normotensive animals. Present results support that brain ETA are not
involved in blood pressure regulation in normal rats, but they significantly contribute to chronic
blood pressure elevation in hypertensive animals. Changes in TH activity and expression were
observed in the right but not in the left OB, supporting functional asymmetry, in line with previous
studies regarding cardiovascular regulation. Present findings provide further evidence on the
role of ETs in the regulation of catecholaminergic activity and the contribution of the right OB to
DOCA-salt hypertension.
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1. Introduction
Hypertension is a multifactorial disease characterized by chronic elevation of systolic and/or
diastolic blood pressure (BP) above 140 mmHg and/or 90 mmHg, respectively [1,2]. The etiology
and pathophysiological mechanisms involved in the development and maintenance of hypertension
remain to be fully elucidated, although strong evidences support a major role for the sympathetic
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nervous system and the renin angiotensin system. It is well established that neural and non-neural
factors contribute to the development of hypertension [3,4]. Neural factors are characterized by an
increase in central sympathetic activity. In this sense, ablation of the area postrema or anteroventral
third ventricle (AV3V) Brody’s area prevents BP elevation and decreases norepinephrine levels in the
brainstem of DOCA-salt rats [5,6]. Non-neural factors include vasoactive peptides such as vasopressin,
angiotensin II, natriuretic peptide, and endothelins (ETs) acting at the peripheral or brain level [3,7].
Among the different animal models for hypertension research, the DOCA-salt model is suitable for
addressing two of the major pathways involved in hypertension as well as the significant contribution
of factors like ETs [8].
ETs comprise a family of three structurally related 21-amino acid peptides (ET-1, ET-2, and ET-3)
which are widely distributed in the body, including the central nervous system (CNS) [9,10]. ETs
are potent vasoconstrictor substances intimately involved in the regulation of BP and cardiovascular
function. In the brain, ETs modulate catecholaminergic transmission, although little is known about
their participation in the central regulation of cardiovascular physiology and pathophysiology [9–15].
ETs mediate their biological effects through two well characterized G-protein coupled receptors, ETA
and ETB [10,16,17]. Several authors support the existence of atypical or non-conventional receptors
based on the observation of atypical responses to the ET agonists and antagonists that characterize the
conventional receptors [13,14,16,18]. However, at present no additional ET receptors have been cloned.
Peripheral ETA blockade revealed that this receptor subtype is involved in the origin of chronic BP
elevation in different animal models of hypertension [9,10,19]. In contrast, ETB activation has a dual
role on the regulation of the vascular tone; it induces vasodilatation through the release of nitric oxide
and prostacyclin followed by sustained vasoconstriction [9,16]. ETs applied to the brain increase BP,
modify neurohormone release, and augment plasma catecholamine levels [9,10]. However, the role
of brain ET receptors in the regulation of BP in both normotensive and hypertensive animals has not
been fully elucidated.
The CNS has a key role in the short and long-term regulation of BP [20,21]. ETs and their receptors
are expressed in numerous brain regions and areas related to the control of BP and cardiac function like
the rostral ventrolateral medulla, nucleus of the solitary tract, the hypothalamus, the locus coeruleus,
and the amygdala [9,22]. However, increasing evidence suggests that the olfactory bulb (OB), which
expresses ET receptors, also contributes to BP regulation. The OB is an extension of the rostral
telencephalon, which projects to the hypothalamus, locus coeruleus, and other brain regions intimately
involved in cardiovascular regulation [23,24].
The OB in humans was long considered to be just involved in olfaction, but different reports show
that this brain area directly or indirectly contributes to the regulation of functions others than olfaction.
Although the OB in humans is smaller than in rats, the number of neurons is similar, and, further,
it is even larger in absolute terms [25]. Several studies show that the OB ablation results in critical
changes in both dopamine and norepinephrine levels and in the activity of monoamine oxidase in
the brainstem and, further, it attenuates cardiovascular sympathoexcitatory reflexes in rats [23,26,27].
A recent work shows that patients with congenital heart disease show subtle dysplasia of discrete
brain regions, including the OB, which is associated with delayed brain maturation [28].
We previously reported that ETs applied to the brain modulate noradrenergic transmission
(biosynthesis, neuronal release, and uptake of norepinephrine) in the anterior and posterior
hypothalamus as well as in the OB of both normotensive and DOCA-salt hypertensive rats [11–15].
In recent studies, we showed that the acute administration (1 h) of an ETA antagonist (BQ610) or an ETB
agonist (IRL1620) in the rat brain lateral ventricle modulates tyrosine hydroxylase (TH) expression and
its phosphorylated forms in the anterior and posterior hypothalamus as well in the OB. Furthermore,
these treatments induce an acute decrease in systolic BP in DOCA-salt hypertensive rats (unpublished
observations).
The expression of the endothelinergic system and the presence of catecholaminergic neurons
in the OB as well as the extensive network of afferent/efferent connections between this
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telencephalic structure and areas involved in cardiovascular regulation suggest that the modulation of
catecholaminergic activity by ETs in the OB may contribute to BP modulation.
In the present study, we sought to establish the role of ETA in the regulation of catecholaminergic
activity in the right and left OB of normotensive and DOCA-salt hypertensive rats. Time course systolic
BP and heart rate (HR) were also registered. Catecholaminergic activity in the OB was assessed by
possible transcriptional, traductional, and post-traductional changes of TH, which is the rate-limiting
enzyme in catecholamine biosynthesis. Studies were performed in the right and left OB to evaluate
possible functional asymmetry, as reported by previous cardiovascular studies. Results showed that
ETA blockade had no effect on normotensive animals, but it significantly reduced systolic BP and
prevented the increase in TH activity and expression in the right OB of hypertensive animals.
2. Results
2.1. Central ETA Blockade Decreased Systolic BP in DOCA-Salt Hypertensive Rats
As previously reported, systolic BP was significantly increased in DOCA-salt rats as compared
to normotensive animals (156 ± 2 mmHg vs. 120 ± 1 mmHg) (Figure 1). However, no changes in
HR (365 ± 3 beats/min (BPM) and DOCA-salt rats 367 ± 5 BPM) were observed in either group
(Figure 2a). Blockade of ETA by BQ610 for a week induced no significant modifications in systolic
BP or heart rate in normotensive animals (Figures 1b and 2b). In the absence of BQ610, DOCA-salt
hypertensive animals further increased systolic BP by 8.3% (169 ± 2 mmHg). Conversely, systolic BP
dose-dependently decreased in the presence of the antagonist. BQ610 at 12 ng/h decreased systolic
BP by approximately 27 mmHg whereas at 24 ng/h it diminished it by 40 mmHg (Figure 1b). No
significant differences were observed in HR following ETA blockade (Figure 2b). Systolic BP and HR
values are detailed in Tables 1 and 2.
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Figure 1. Systolic blood pressure (BP) following ET receptor type A (ETA) blockade by BQ610 in 
normotensive and deoxycorticosterone acetate (DOCA)-salt hypertensive rats. Systolic BP was 
measured by tail-cuff plethysmography as described in Materials and Methods and expressed in 
mmHg ± SEM. (a) Basal systolic BP. Basal values were registered 48 h before BQ610 administration. 
*** p < 0.001 vs. control. (b) Time course of systolic BP. Systolic BP was registered following BQ610 
administration at 24, 48, 72, 96, 120, and 144 h. * p < 0.05, ** p < 0.01, and *** p < 0.001 vs. the respective 
time control; ††† p < 0.001 vs. the respective time DOCA-salt. (c) Average systolic BP. Each bar 
represents the area under each curve (shown in b) between 0 and 144 h. *** p < 0.001 vs. control;  
††† p < 0.001 vs. DOCA-salt; ‡‡‡ p < 0.001 vs. DOCA-salt + BQ610. Number of animals: control, 17; BQ610 
(12 ng/h), 12; BQ610 (24 ng/h), 8; DOCA-salt, 17; DOCA-salt + BQ610 (12 ng/h), 11; and DOCA-salt + 
BQ610 (24 ng/h), 10. 
 
Figure 1. Systolic blood pressure (BP) following ET receptor type A (ETA) blockade by BQ610
in normotensive and deoxycorticosterone acetate (DOCA)-salt hypertensive rats. Systolic BP was
measured by tail-cuff plethysmography as described in Materials and Methods and expressed in
mmHg ± SEM. (a) Basal systolic BP. Basal values were registered 48 h before BQ610 administration.
*** p < 0.001 vs. control. (b) Time course of systolic BP. Systolic BP was registered following BQ610
administration at 24, 48, 72, 96, 120, and 144 h. * p < 0.05, ** p < 0.01, and *** p < 0.001 vs. the
respective time control; ††† p < 0.001 vs. the respective time DOCA-salt. (c) Average systolic BP. Each
bar represents the area under each curve (shown in b) between 0 and 144 h. *** p < 0.001 vs. control; †††
p < 0.001 vs. DOCA-salt; ‡‡‡ p < 0.001 vs. DOCA-salt + BQ610. Number of animals: control, 17; BQ610
(12 ng/h), 12; BQ610 (24 ng/h), 8; DOCA-salt, 17; DOCA-salt + BQ610 (12 ng/h), 11; and DOCA-salt +
BQ610 (24 ng/h), 10.
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Figure 2. Heart rate (HR) following ETA blockade by BQ610 in both normotensive and DOCA-salt 
hypertensive rats. HR was assessed as detailed in Materials and Methods and expressed as beats per 
minute ± SEM. (a) Basal HR. Basal values were registered 48 h before BQ610 administration; (b) Time 
course of HR. HR was registered following BQ610 administration at 24, 48, 72, 96, 120, and 144 h; (c) 
Average HR. Each bar represents the area under each curve (shown in b) between 0 and 144 h. 
Number of animals: control, 17; BQ610 (12 ng/h), 12; BQ610 (24 ng/h), 8; DOCA-salt, 17; DOCA-salt + 
BQ610 (12 ng/h), 11; and DOCA-salt + BQ610 (24 ng/h), 10. 
Table 2. Heart rate (HR) values following ETA blockade. HR is expressed as beats per minute (BPM) 
± SEM. C, normotensive control; DOCA, DOCA-salt hypertensive rats. Number of animals: control, 
17; BQ610 (12 ng/h), 12; BQ610 (24 ng/h), 8; DOCA-salt, 17; DOCA-salt + BQ610 (12 ng/h), 11; and 
DOCA-salt + BQ610 (24 ng/h), 10. 
Experimental Groups 
HR During Long-Term ETA Antagonist Treatment 
24 h 48 h 72 h 120 h 144 h 
Control 367 ± 6 362 ± 6 358 ± 6 363 ± 6 363 ± 6 
C + BQ610 (12 ng/h) 364 ± 5 361 ± 5 367 ± 9 355 ± 10 348 ± 7 
C + BQ610 (24 ng/h) 357 ± 7 356 ± 8 345 ± 3 364 ± 5 358 ± 5 
DOCA-salt 347 ± 7 359 ± 9 349 ± 11 366 ± 9 356 ± 8 
DOCA + BQ610 (12 ng/h) 356 ± 6 365 ± 9 348 ± 8 360 ± 7 349 ± 8 
DOCA + BQ610 (24 ng/h) 359 ± 11 364 ± 8 351 ± 7 371 ± 9 359 ± 10 
2.2. ETA Blockade Prevented the Increase in TH Activity in the Right OB of Hypertensive Rats 
In order to determine whether ETA blockade affected the catecholaminergic system in the OB, 
TH activity was assessed (Figure 3). ETA blockade by BQ610 at 12 ng/h or at 24 ng/h induced no 
changes in TH activity in normotensive animals. DOCA-salt hypertensive rats showed enhanced TH 
activity in the right OB (~45%), but the increase in the enzyme activity was prevented by ETA blockade 
Figure 2. Heart rate (HR) following ETA blockade by BQ610 in both normotensive and DOCA-salt
hypertensive rats. HR was assessed as detailed in Materials and Methods and expressed as beats
per minute ± SEM. (a) Basal HR. Basal values were registered 48 h before BQ610 administration;
(b) Time course of HR. HR was registered following BQ610 administration at 24, 48, 72, 96, 120, and
144 h; (c) Average HR. Each bar represents the area under each curve (shown in b) between 0 and 144 h.
Number of animals: control, 17; BQ610 (12 ng/h), 12; BQ610 (24 ng/h), 8; DOCA-salt, 17; DOCA-salt +
BQ610 (12 ng/h), 11; and DOCA-salt + BQ610 (24 ng/h), 10.
Table 1. Systolic blood pr ssure (BP) values following ET receptor type A (ETA) blockade. Systolic BP
was expressed as mmHg ± SEM. C, normotensive control; DOCA, DOCA-salt hypertensive rats.
Experimental Groups Systolic BP Following ETA Blockade by BQ610
24 h 48 h 72 h 120 h 144 h
Control 114.1 ± 2.3 113.0 ± 2.2 113.7 ± 2.7 114.4 ± 2.3 115.8 ± 2.5
C + BQ610 (12 ng/h) 117.5 ± 2.4 NS 117.9 ± 3.0 NS 116.6 ± 2.3 NS 119.8 ± 2.7 NS 115.1 ± 3.9 NS
C + BQ610 (24 ng/h) 117.2 ± 1.9 NS 118.8 1.5 NS 120.7 ± 3.2 NS 120.1 ± 1.9 NS 118.3 ± 3.3 NS
DOCA-salt 164.1 ± 2.6 *** 168.5 ± 3.7 *** 170.1 ± 4.1 *** 168.7 ± 2.6 *** 173.1 ± 4.2 ***
DOCA + BQ610 (12 ng/h) 134.7 ± 3.3 ***,††† 138.8 ± 5.8 ***,††† 141.5 ± 4.5 ***,††† 149.5 ± 3.0 ***,††† 143.9 ± 5.6 ***,†††
DOCA + BQ610 (24 ng/h) 124.1 ± 3.8 ††† 125.2 ± 3.7 *,††† 129.6 ± 3.2 **,††† 130.8 ± 3.0 **,††† 132.8 ± 3.7 ***,†††
* p < 0.05, ** p < 0.01, and *** p < 0.001 vs. control; ††† p < 0.001 vs. DOCA-salt. Number of animals: control, 17;
BQ610 (12 ng/h), 12; BQ610 (24 ng/h), 8; DOCA-salt, 17; DOCA-salt + BQ610 (12 ng/h), 11; and DOCA-salt +
BQ610 (24 ng/h), 10. NS: Not significant.
Table 2. Heart rate (HR) values following ETA blockade. HR is expressed as b ats per minute (BPM)
± SEM. C, normotensive control; DOCA, DOCA-salt hypertensive rats. Number of a imals: control,
17; BQ610 (12 ng/h), 12; BQ610 (24 ng/h), 8; DOCA-salt, 17; DOCA-salt + BQ610 (12 ng/h), 11; and
DOCA-salt + BQ610 (24 ng/h), 10.
Experimental Groups HR During Long-Term ETA Antagonist Treatment
24 h 48 h 72 h 120 h 144 h
Control 367 ± 6 362 ± 6 358 ± 6 363 ± 6 363 ± 6
C + BQ610 (12 ng/h) 364 ± 5 361 ± 5 367 ± 9 355 ± 10 348 ± 7
C + BQ610 (24 ng/h) 357 ± 7 356 ± 8 345 ± 3 364 ± 5 358 ± 5
DOCA-salt 347 ± 7 359 ± 9 349 ± 11 366 ± 9 356 ± 8
DOCA + BQ610 (12 ng/h) 356 ± 6 365 ± 9 348 ± 8 360 ± 7 349 ± 8
DOCA + BQ610 (24 ng/h) 359 ± 11 364 ± 8 351 ± 7 371 ± 9 359 ± 10
2.2. ETA Blockade Prevented the Increase in TH Activity in the Right OB of Hypertensive Rats
In order to determine whether ETA blockade affected the catecholaminergic system in the OB, TH
activity was assessed (Figure 3). ETA blockade by BQ610 at 12 ng/h or at 24 ng/h induced no changes
in TH activity in normotensive animals. DOCA-salt hypertensive rats showed enhanced TH activity in
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the right OB (~45%), but the increase in the enzyme activity was prevented by ETA blockade (Figure 3).
Nevertheless, no changes in TH activity were observed in the left OB of hypertensive animals in the
presence or absence of BQ610 (Figure 3).
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Figure 3. Tyrosine hydroxylase (TH) activity in the left and right olfactory bulb. TH activity was
assessed as detailed in Materials and Methods in the left and right OB of normotensive rats (control) and
DOCA-salt hypertensive rats. TH activity was expressed as percentage of control ± SEM (% control).
*** p < 0.001 vs. control; ††† p < 0.001 vs. DOCA. Number of animals: control, 5; BQ610 (12 ng/h),
3; BQ610 (24 ng/h), 3; DOCA-salt, 4; DOCA-salt + BQ610 (12 ng/h), 3; and DOCA-salt + BQ610
(24 ng/h), 3.
2.3. ETA Blockade Prevented the Increased Expression of TH and Its Phosphorylated Forms in the Right OB of
Hypertensive Rats
We next evaluated whether ETA blockade modified the expression of total TH and
phosphorylation at serine 19 (Ser19p), 31 (Ser31p), and 40 (Ser40p) sites. Representative immunoblots
are shown in Figure 4a. Blockade of ETA by BQ610 (12 and 24 ng/h) did not modify total TH
expression or its phosphorylated forms in the OB of normotensive rats, but it prevented the increase
observed in the right OB of DOCA-salt hypertensive animals (Figure 4). However, in the left OB of
hypertensive rats, total TH or its phosphorylated forms did not change in the absence or presence of
BQ610 (Figure 4b).
2.4. Increased TH mRNA Expression in the Right OB of Hypertensive Rats Was Inhibited by ETA Blockade
TH mRNA expression was assessed in the OB of normotensive and hypertensive rats to evaluate
whether long-term ETA blockade affected the catecholaminergic system (Figure 5). ETA inhibition did
not affect TH mRNA expression in the OB of normotensive rats. The increase in TH mRNA observed
in the OB of DOCA-salt hypertensive rats was prevented by BQ610 at 12 and 24 ng/h (Figure 5). No
changes in TH xpression were observed in the left OB of hypertensive animals with or without BQ610
(Figure 5).
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Representative immunoblots; (b) Densitometric analysis of TH expression and its phosphorylated 
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Figure 4. Expression of total tyrosine hydroxylase (TH) and its phosphorylated forms following
ETA blockade in the left and right olfactory bulb of normotensive and DOCA-salt hypertensive rats.
(a) Representative immunoblots; (b) Densitometric analysis of TH expression and its phosphorylated
levels (Ser19p TH, Ser31p TH, Ser40p TH) in the left and right OB. Results are expressed as percentage
of control ± SEM (% control). * p < 0.05, ** p < 0.01, and *** p < 0.001 vs. control; † p < 0.05, †† p < 0.01,
and ††† p < 0.001 vs. DOCA-salt. Number of animals for each experimental group: 4.
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Figure 5. Tyrosine hydroxylase R expression in the left and right olfactory bulb of normotensive
and DOCA-salt hypertensive rats. as assessed by real time PCR as detailed in Materials
and Methods. Results are expr tage of control ± SEM (% control). *** p < 0.001 vs.
control; †† p < 0.00 -salt. Number of animals: 4 in all experimental groups.
3. Discussion
The present study shows that the brain endothelinergic system is a key factor in the long-term
regulation of catecholaminergic transmission in the OB of DOCA-salt hypertensive rats by increasing
TH mRNA and protein expression as well TH activity. The major evidence to support it was that
central ETA blockade prevented the increase in catecholaminergic activity in the OB of hypertensive
rats and, furthermore, it correlated well with the decrease in systolic BP without changes in the HR.
These observations together with previous findings support the role of the OB in the progression and
maintenance of chronic BP elevation in this animal model of hypertension.
Increasing evidence arising from hu an and animal studies supports that the overactivation
of the sympathetic nervous system and the imbalance of the renin angiotensin system are crucial
events involved in the pathogenesis of hypertensi n. The DOCA-salt model, i dependent of genetic
components, is suitable for studyi g these two major pathways [8]. In addition, in this animal model
ETs play a elevant role in the genesis of chronic BP elevation [3,8,29].
Four different aspects should be considere in the analysis of the present findings: (1) the increase
in catecholaminergic activity limited to the right OB; (2) the asymmetrical behavior displayed by OB
hemi portions; (3) the effect of brain ETA blockade on the catecholaminergic system in the OB; (4) the
effect of ETA blockade on cardiovascular parameters.
The olfactory system, including the OB, is responsible for processing the olfactory information
from the external environment. Extensive afferent and efferent connections exist between the olfactory
system and other brain areas involved in the regulation of autonomic and behavioral responses,
supporting a wide spectrum of biological functions. Increasing evidence supports that the OB
contributes in a direct or indirect way to the regulation of cardiovascular function [23,26,27]. The
OB integrity is crucial for the CNS to trigger normal sympathoexcitatory responses to diverse
physiological stimuli [27]. Moreover, it was shown that cervical stimulation activatesα-adrenoreceptors
in the OB, leading to venous constriction [30]. Structurally, the OB is formed by several concentric
layers. In the glomerular layer, where the integration of sensory information occurs, a great number
of gamma-am obutyric acid (GABA)ergic and dopaminergic neurons coexist, [31]. I this layer,
catecholaminergic activity is mediated by dopamine b t also by norepinephrine released by nerve
endings originated in the locus coeruleus. Enhanced norepinephrine turn-over and chang s in
the spontaneous firing rate of t ese neurons are observed in hypertension [26,32–34]. The specific
marker of catecholaminergic neurons is TH, which catalyzes the rate limiting step in catecholamine
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biosynthesis [35,36]. Both TH mRNA and protein were reported in the periglomerular neurons of the
rat OB [37,38].
Our laboratory was the first to report that ETs enhance noradrenergic transmission in the OB of
normotensive rats, supported by short-term increased TH activity and norepinephrine release [39].
In that study, we show that ETs increase TH activity through ET receptor activation coupled to the
stimulation of protein kinase A (PKA) and C (PKC), as well as Ca2+/calmodulin-dependent protein
kinase II (CaMKII). Kinase activation by ETs induces TH phosphorylation at Ser-19 and Ser-40 sites,
leading to enhanced TH activity [39]. Moreover, the increase in norepinephrine release stimulated by
ETs in the OB suggests that it contributes to enhance TH activity by reducing the feedback inhibition
evoked by the amine. In a later study, we reported that long-term exposure to ETs enhances TH mRNA
and the expression of total TH and its phosphorylation forms in normotensive rats [14]. Furthermore,
to our knowledge, we were the first to report that in the right OB of DOCA-salt hypertensive rats TH
activity and expression as well as neuronal norepinephrine release were increased whereas the uptake
of the amine was diminished [40].
In the present work, we show that catecholaminergic transmission was enhanced in DOCA-salt
hypertensive rats even in the long-term. TH activity was augmented, as supported by enhanced
enzyme expression and phosphorylation. The major short-term mechanism of TH activation is protein
kinase-induced phosphorylation of serine residues [35,36], whereas the mRNA expression and stability
of the enzyme are the main long-term regulatory mechanisms. We show that phosphorylation of
TH at Ser-40, 31, and 19 sites was increased in hypertensive animals. Phosphorylation at Ser-40
site substantially increases TH activity, leading to the inhibition of the catecholamine-mediated
inhibitory feedback mechanism [35,36]. Ser-40 is considered the most promiscuous site, since it
can be phosphorylated by various kinases like PKA, PKC, CaMK-II, and PKG. Phosphorylation at
Ser-31 by ERK1 and ERK2 results in a modest increase in TH activity whereas phosphorylation at
Ser-19 site by ERK1/2 and CaMK-II results in a Ser-40 enhanced phosphorylation rate due to changes
in the enzyme conformation [35,36]. In addition, it was suggested that TH phosphorylation in response
to physiological stimuli induces a more active, although less stable, form of the enzyme [35,36]. In the
present study, the observation that TH mRNA and total protein expression were enhanced in the right
OB of DOCA-salt rats supports positive long-term regulation of the catecholaminergic transmission.
Changes in TH activity were reported in other regions and areas of the CNS in various animal
models of hypertension including the DOCA-salt model [15,41,42]. A few reports in the literature
address the steps of noradrenergic transmission in the brain of DOCA-salt rats studied herein. In this
sense, Rylett et al. [43] reported that TH activity is enhanced in the whole brain, whereas Nagaoka and
Lovenberg [44] showed that it is reduced in the hypothalamus. Recent studies from our laboratory
show an increase in ETA density, as well as in TH expression in the OB of DOCA-salt hypertensive
animals. Furthermore, acute brain ETA blockade (1 h) by BQ610 significantly decreases the expression,
phosphorylation, and therefore the activity of TH in the OB of these animals. Also, a differential
modulation of catecholaminergic activity in the hypothalamus of DOCA-salt rats occurs due to both
short- (1 h) and long-term (7 days) ETA blockade (unpublished observations). These results support
present findings. The observed long-term upregulation in catecholaminergic transmission in the
right OB may contribute, at least in part, to the development, maintenance, and/or progression of
hypertension in this salt-dependent animal model. Furthermore, these results support an excitatory
role of this telencephalic region by increasing sympathetic activity.
Present findings also reveal an asymmetrical response between the right and left hemi portions of
the OB, with the right hemi-portion being the one that showed important changes, both by DOCA-salt
hypertension and chronic ETA treatment (this point will be discussed later). In the left OB, the
catecholaminergic activity was unchanged. We previously reported an asymmetrical behavior in the
OB of DOCA-salt rats and non-asymmetrical differences in normotensive animals [40]. The existence of
brain asymmetry, including norepinephrine levels in the hypothalamus, has been reported in distinct
animal species [45]. A study shows the existence of an asymmetrical descending cardiovascular
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pathway in the dorsomedial hypothalamus supported by the observation that activation of the right
OB induces higher HR than activation of the left hemi-portion [46]. An anatomical asymmetry
between both hemi-portions of the OB was also shown, where the right side is larger than the left [47].
In regard to hypertension, the present findings are in line with previous studies that support that the
right brain region is more associated with the control of cardiovascular function [46,48]. It was shown
that patients with essential hypertension evoke higher norepinephrine release in the right jugular
vein [49]. Moreover, higher tachycardia is observed upon stimulation of the right sinoatrial node
as compared with the left node [50,51]. These studies support that the right sympathetic nervous
system would control HR. In addition, the right insular cortex evokes an asymmetrical sympathetic
response as compared with the left hemi-portion [48,52]. This report gives further evidence that HR
and BP are controlled by the right hemi-portion, since this brain area contains neurons involved in
the baroreflex regulation [45,48]. It has also been reported that lipopolysaccharide injection to mice
induces sympathoexcitation induced by norepinephrine release in the right region [53]. The right
kidney of hypertensive patients without renal stenosis evokes a higher sympathetic discharge than
the left [54]. In summary, most studies provide strong evidence that in hypertension, norepinephrine
release is increased in right brain areas, thus supporting that cardiovascular regulation is asymmetrical.
Although brain functional asymmetry regarding cardiovascular regulation has been widely reported
and our results agree in the same way, its physiological relevance remains elusive.
ETs and their receptors are expressed in diverse regions and areas of the CNS including the
OB [9,10]. The existence of both endothelinergic and catecholaminergic systems in the OB suggests
the modulation of noradrenergic transmission by ETs in this region, as has been shown in other
brain areas [11–14,39]. In the present study, we addressed the impact of chronic (7 days) central
ETA blockade on normotensive and hypertensive rats. Results support that the catecholaminergic
activity in normotensive animals is not influenced by ETs acting through ETA receptors. However,
in hypertensive animals, overactivity of the catecholaminergic activity in the right OB, supported
by enhanced TH expression and activity, was prevented by ETA blockade. Our findings strongly
support an interaction along time between the endothelinergic and catecholaminergic system in the
OB of DOCA-salt hypertensive rats. Catecholaminergic activity seems to be dependent on the central
endothelinergic system in hypertension. However, current evidence does not allow us to state whether
this relationship is direct or if other mechanisms are also involved.
In the present study, the specific ETA antagonist (BQ610) was applied into the brain ventricle to
act on areas where ET receptors are expressed. The OB presents ETA receptors, and the antagonist
would reach the OB because the ventricular system of the brain contacts this area. In addition, the
cerebrospinal fluid in the rat is close to 300 µL and circulates at an average flow of 132 µL/h, and
the volume in the lateral ventricle (approximately 50 µL) is replaced almost three times in that time
lapse [55]. Therefore, the antagonist can diffuse assisted by the ventricular microcirculation and the
flow caused by the osmotic infusion pump that releases it at a constant rate (0.12 µL/h). However,
we cannot assure whether ETA blockade occurs directly in the OB and/or in other brain areas or if
our findings result from a more general effect which leads to the modulation of the catecholaminergic
activity in this telencephalic region. In any case, we can confirm that brain ETA blockade modulates,
even in the long term, the activity of the catecholaminergic system in the OB of DOCA-salt hypertensive
animals either in a direct or an indirect way.
To analyze the interaction between the central endothelinergic system and the catecholaminergic
transmission in the OB in the context of DOCA-salt hypertension, various aspects should be considered.
The OB makes contact with different telencephalic, mesencephalic, diencephalic, and brainstem
regions [26], some intimately involved in the control of the cardiovascular function. For instance, the OB
interacts with the nucleus of the solitary tract, which is the primary site for the integration of baroreflex
input [56,57]. In addition, areas like the amygdala, the septum, the piriform, and orbitofrontal cortex, as
well as the ventromedial and posterior nucleus of hypothalamus, connect with the OB. All these areas
play an important role in the regulation of cardiovascular function [23,58,59], thus supporting that the
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OB is likely a relevant actor in this complex mechanism. In this sense, Nagai et al. support the existence
of a relationship between olfaction, autonomic balance, and cardiovascular physiology [60]. The
exposure of conscious rats to smoke generates changes in BP, breathing, and sympathetic activity [61].
It is important to consider that the OB integrity is necessary in rats to induce normal sympathoexcitatory
responses to distinct physiological stimuli. In this sense, bulbectomized rats exhibit an attenuated
response to hypotension, endocrine alterations, as well as elevated basal BP and HR [23,24,26,27].
Some authors postulate that the impaired cardiovascular physiology observed under this situation
results from changes in the autonomic regulation [62,63]. In this regard, Kelly et al. [26] showed that
the cardiovascular changes in bulbectomized rats are associated with changes in the neurochemistry
of several neurotransmitters, including norepinephrine. Bilateral olfactory bulbectomy is also a
validated animal model of depression that shows diverse functional changes in norepinephrine,
dopamine, serotonin, acetylcholine, glutamate, GABA, and monoamine oxidase activity [24,26,29].
It was suggested that this model exerts a strong influence not only on emotions but also on the central
control of BP and HR [23]. Although some studies show a bidirectional relationship between depression
and cardiovascular diseases, the underlying mechanisms still remain unknown [62,64]. Various studies
support that depression leads to the development of cardiovascular diseases by inducing changes in
the autonomic regulation [65,66]. In this sense, it was reported that patients with depression exhibit
increased HR and sympathetic nervous system activity, as well as baroreflex impairment [64,67].
Several vasoactive peptides, including angiotensin II, natriuretic peptides, and ETs are present in
the OB [68–70]. ETs behave as neurotransmitters and/or neuromodulators within the CNS. Different
works support that the effects of ETs in the brain are mediated by changes in the sympathetic nervous
system [9,16]. ETs applied to the brain modify BP, HR, and behavior [9,16]. Although growing evidence
supports the participation of the OB in the regulation of BP and cardiovascular activity, little is known
about its contribution to hypertension. However, direct evidence suggests that enhanced sympathetic
activity is a key factor in DOCA-salt hypertension. In this animal model, plasma catecholamines are
increased [3]. In addition, in early and established DOCA-salt hypertension, ganglionic blockade
evokes a higher decrease in BP [71]. Peripheral sympathectomy in this animal model prevents enhanced
plasma norepinephrine and hypertension [46].
In the present work, the changes in the catecholaminergic activity in the right OB of DOCA-salt
hypertensive animals were in accordance with the modifications in systolic BP, further supporting
the role of the OB in cardiovascular regulation. Cardiovascular parameters were not affected by
ETA blockade in normotensive animals, suggesting that brain ETA receptors are not involved in the
physiological control of BP. However, this receptor subtype in the brain appears to have a key role in
DOCA-salt hypertension, given that ETA inhibition by BQ610 dose-dependently decreased systolic
BP. Although following the administration of the ETA antagonist systolic BP decreased, no changes
were observed in HR. It has been previously reported the baroreceptor reflex is impaired in DOCA-salt
hypertension [8,72]. It is likely that the fall in BP following ETA antagonist applied to the brain may
result from decreased sympathetic activity controlled by the brain, which may in turn affect stroke
volume but mainly peripheral vascular resistance. In addition, activation of ETB by endogenous ETs
could play a role in this mechanism. However, the underlying mechanism(s) that induce(s) BP decrease
by brain ETA blockade remains to be established.
Taken together, in consideration of previous and present findings, it is possible to hypothesize
the existence of a close and strong relationship between the central endothelinergic system and
the asymmetric catecholaminergic transmission in the OB of hypertensives rats. This interaction
would play an important role in the brain modulation of the cardiovascular function in DOCA-salt
hypertension. The present study presents evidence for the role of the OB in salt-dependent
hypertension. However, additional experimental and clinical studies are necessary to prove that
the present findings may have clinical implications in humans. Understanding the role of brain areas
indirectly or directly related to the regulation of cardiovascular function that have been relegated or
poorly studied may favor not only the scientific knowledge itself but also the development of new
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therapeutic tools for the prevention and/or treatment of hypertension, a disease which nowadays
exhibits greatest morbidity and mortality on a global scale.
4. Materials and Methods
4.1. Animals and Experimental Design
Seventy-five Sprague-Dawley male rats with an approximate body weight of 150 g were used
(Animal Facility of the School of Pharmacy and Biochemistry, University of Buenos Aires, Buenos
Aires, Argentina). Animals were housed in steel cages and maintained under constant temperature and
humidity conditions, with 12 h light/dark cycles and food provided ad libitum under the supervision
of a professional Technician. All experiments were performed following the principles of the Guide for
Care and Use of Laboratory Animals and the International Guiding for Biomedical Research Involving
Animals [73,74]. All experiments were approved by the Institutional Committee on Care and Use of
Laboratory Animals (CICUAL) at the School of Pharmacy and Biochemistry, University of Buenos
Aires (Note 031013-5; Exp-FYB N◦ 56106/2013, 8 August 2013). All efforts were made to minimize the
number of rats and stress caused.
Animals were randomly divided into two groups: control (normotensive) and DOCA-salt.
DOCA-salt hypertension was induced by two subcutaneous weekly injections of 15 mg/kg of
deoxycorticosterone acetate (DOCA) (MP Biomedicals, Santa Ana, CA, USA) dissolved in sesame
seed oil (vehicle) and by administration of 1% NaCl in water for five weeks. Normotensive control
animals were injected with vehicle and drank tap water. Body weight and water consumption were
determined twice a week for all rats. Also, systolic BP and HR were registered by Non-Invasive Blood
Pressure (NIBP) controller and PowerLab 8/30 data acquisition (ADInstruments Model 125 and Model
ML 870, respectively; Pty Ltd., Sydney, Australia) using a Pulse Transducer for Rat (Panlab/Harvard
Apparatus, Barcelona, Spain). One week before the administration of the first DOCA injection, animals
were manipulated by the operator who eventually administered the DOCA and made BP recording.
BP measurements were performed in a quiet room where animals were previously acclimatized
for a 1-h period. To minimize stress, no restraint tubes were used, but a dark cover was placed over
the animals [75,76]. Daily, the operator manipulated the animal, placed it on a heating pad (32–34 ◦C),
put a dark blanket over the animal, placed the occlusion cuff on the animal, and, when the animal
was quiet, inflated the cuff. In our experience, with this habituation protocol, no restraint tubes are
necessary because the animal gets familiar with the operator and the procedure. As supported by the
literature, methodology considerations optimize the operative capacity to measure systolic BP and HR
in normal or experimental conditions by tail-cuff plethysmography [75,77]. As advised, three to eight
measurements per animal were registered [75]. Measurements were recorded between 10 a.m. to 2 p.m.
to avoid circadian variations [78]. It is important to consider that if the methodology recommendations
for the tail cuff method are followed, the values of systolic BP and HR are similar to those obtained by
telemetry [79,80].
At week 4, animals were anesthetized with ketamine/xylazine (80/10 mg/kg, IP) and underwent
intracerebroventricular (ICV) stereotaxic surgery (David Kopf Mod. 900, Tujunga, CA, USA). ICV
surgery was performed according to The Rat Brain at Stereotaxic Coordinates [81] and using a brain
infusion kit (B.I.K.1, DURECT Co., Cupertino, CA, USA). The cannula was kept connected all time
to an osmotic microinfusion pump (ALZET model 1004; DURECT Co.) located subcutaneously in
the middle scapular region of the animal. The osmotic microinfusion pump vehiculized the ETA
antagonist BQ610 at two different concentrations: 100 ng/µL (constant flow 12 ng/h) or 200 ng/µL
(constant flow 24 ng/h) for 7 days continuously, in both cases dissolved in artificial cerebrospinal fluid
(aCSF, vehicle) of a composition recommended by ALZET, DURECT Co. One-third of the animals in
each group received osmotic microinfusion pumps loaded with 100 µL of BQ610 (12 ng/h), another
third loaded with 100 µL of BQ610 (24 ng/h), and the remaining third with a pump loaded with 100
µL of aCSF. In this way, six different treatments were formed (Table 3).
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Table 3. Experimental groups used in the present study.
Groups ETA Antagonist/Vehicle Doses
Control Vehicle
Control + BQ610 BQ610 12 ng/h
Control + BQ610 BQ610 24 ng/h
DOCA-salt Vehicle
DOCA-salt + BQ610 BQ610 12 ng/h
DOCA-salt + BQ610 BQ610 24 ng/h
At 1 h following surgery and for 48 h, animals orally received proper analgesia and antibiotic
therapy. Systolic and HR were recorded at 24, 48, 72, 120, and 144 h. At week 5, animals were
euthanized by decapitation, brains were removed, and right and left OB were dissected according to
Maps and guide to microdissection of the rat brain [82]. Samples were processed for total RNA and
proteins extraction, or for TH activity determination.
4.2. Methods
4.2.1. TH Activity
Tissues were homogenized in 200 µL lysis buffer (5 mM KH2PO4 and 2% Triton 100X, pH 7.0). Cell
debris was removed by centrifugation at 12,500 rpm for 10 min at 4 ◦C. An aliquot of the supernatant
was saved for protein quantification. TH activity was determined by the technique described by
Reinhard et al. [83]. Briefly, samples were incubated for 20 min at 37 ◦C with the reaction solution
(50 mM HEPES, pH 7.0; 15 nmol 3H-L-tyrosine (PerkinElmer Life and Analytical Sciences, Billerica,
MA, USA), 420 mM β-mercaptoethanol, and 1000 U catalase). The reaction was stopped by cold and
an aliquot of the reaction mixture was placed in 1 N HCl with an activated charcoal suspension (7.5%
w/v). Following centrifugation for 10 min at 4 ◦C, supernatants were recovered to measure 3H2O by
liquid scintigraphy (WinSpectral 1414 counter, Perkin Elmer/Wallac, Ramsey, MN, USA). Results were
expressed as percentage of control ± SEM.
4.2.2. Tissue Homogenization for Western Blot Assay and RT-PCR
Total RNA and proteins from OB were isolated by an extraction kit according to the manufacturer’s
specifications (TRIreagent, Molecular Research Center Inc., Cincinnati, OH, USA). To improve the
protein yield isolated by this method, an additional resuspension step was made by using a urea 9.5 M
(Biopack, Buenos Aires, Argentina) in 2% buffer CHAPS solution (Thermo Fischer Scientific, Waltham,
MA, USA).
4.2.3. Western Blot Assay for TH
Experimental procedures for Western blot were as previously detailed [84]. Samples separated on
SDS-PAGE and electro-transferred to PVDF membranes (GE Healthcare, Amersham Biosciences,
Little Chalfont, UK) were then exposed to primary antibodies overnight at 4 ◦C, followed by
horseradish peroxidase (HRP)-conjugated anti-rabbit or anti-mouse antibodies for 1 h at room
temperature. Membranes were developed by a bioluminescent Western blotting detection system
(Kalium Technologies, Buenos Aires, Argentina) and exposed to X-ray films. Bands were analyzed by
densitometry and normalized to β-actin. Primary and peroxidase conjugated secondary antibodies
and dilutions are shown in Table 4.
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Table 4. Antibodies used for western blot assays. Primary and peroxidase-conjugated secondary
antibodies. Catalogue numbers are shown between brackets.
Primary Antibody Dilution Company
Total TH monoclonal (mouse) 1:2000 Sigma, St. Louis, MO, USA (T1299)
Ser19p TH polyclonal (rabbit) 1:4000 Chemicon, Millipore Co., Temecula, CA, USA (AB5425)
Ser31p TH polyclonal (rabbit) 1:750 Chemicon, Millipore Co., Temecula, CA, USA (AB5423)
Ser40p TH polyclonal (rabbit) 1:2000 Chemicon, Millipore Co., Temecula, CA, USA (AB5935)
β-actin monoclonal (mouse) 1:1000 Sigma, St. Louis, MO, USA (A2066)
Secondary Antibody Dilution Company
Anti-mouse (Goat) (for Total TH) 1:5000 Santa Cruz, Dallas, TX, USA (sc2005)
Anti-rabbit (Goat) (for Ser19p TH) 1:7500 Chemicon, Millipore Co., Temecula, CA, USA (AP307P)
Anti-rabbit (Goat) (for Ser31p TH) 1:1500 Chemicon, Millipore Co., Temecula, CA, USA (AP307P)
Anti-rabbit (Goat) (for Ser40p TH) 1:5000 Chemicon, Millipore Co., Temecula, CA, USA (AP307P)
Anti-mouse (Goat) (for β-actin) 1:4000 Santa Cruz, Dallas, TX, USA (sc2005)
4.2.4. Real-Time PCR for mRNA TH
Experimental procedures for mRNA TH were as previously detailed [13] with minor modifications.
Residual DNA co-purified with total RNA was removed by incubation with DNase (TransGen Biotech,
Beijing, China) for 60 min at 37 ◦C. Total RNA quality and quantity was assessed by 1% (w/v) agarose
gel electrophoresis and UV spectrometry, respectively. An amount of 2 µg RNA was retrotranscribed
to cDNA with reverse transcriptase MMLV (Genbiotech, Buenos Aires, Argentina) and RNase inhibitor
(RNasin, Genbiotech, Argentina), dNTPs, and oligo-dT primer (IDT, San Jose, CA, USA). TH or β-actin
(housekeeping) mRNA expression were analyzed in a RotorGene Q-series thermocycler (QUIAGEN,
Hilden, Germany). The oligonucleotide sequences used as primers are summarized in Table 5.
Table 5. Primers sequences used for real time PCR.






TH cDNA amplification product corresponds to an 81 bp fragment between nucleotides 1184–1264
in the original mRNA sequence, whereas the β-actin is 69 bp and is between nucleotides 1090 and
1158 of the original mRNA sequence. Reactions were performed with cDNA, Evagreen fluorochrome
(Biotium, San Francisco, CA, USA), TH, or β-actin specific primer mix (IDT, San Jose, CA, USA), 0.6 µL
MgCl2 50 mM, 0.4 µL dNTPs 10 mM, 4 µL 5× GoTaq buffer, and 0.3 µL GoTaq DNA polymerase
(Promega, Madison, WI, USA) in a 20 µL final volume. Amplification consisted of 35–40 cycles
(denaturation at 94 ◦C for 15 s, hybridization at 54 ◦C for 45 s, and extension at 72 ◦C for 30 s). For
each sample, sequential monitoring once per cycle at the end of extension was performed. Samples
were measured in duplicate. For each primer pair, an external standard RNA concentration curve
was done using pooled RNA samples and confirmed by agarose gel electrophoresis. Melting curve
analysis showed the presence of a single cDNA product per primer pair, thus confirming the specificity
of PCR products. Specificity was further confirmed by agarose gel electrophoresis that showed a
single band of the predicted size for each product. Minor variability among samples were corrected by
normalization of TH expression to β-actin. Relative expression quantification was carried out by the
standard curve method. Results were expressed as percentage of control ± SEM. Sequences of primer
pairs are summarized in Table 5.
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4.3. Statistical Analysis
The statistical analysis was performed using t-test, 1W-ANOVA followed by the Newman-Keuls
comparisons, or 2W-ANOVA followed by the Bonferroni’s comparisons according to the requirement
of each experiment. p-values of 0.05 or less were considered statistically significant.
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